anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Enliven Therapeutics / Imara · press-release

Imara | Mergers and Acquisitions Presentation Deck | 45 slides

45 pages · 5 arc beats · 2 loops

Press-Release Download JSON
Unlock

Imara | Mergers and Acquisitions Presentation Deck | 45 slides

Enliven Therapeutics / Imara · 2022-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 41 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 12 slides 100% 12/12 slides 100% 12/12 slides · 73 hits
— 0/12 slides
16.7% 2/12 slides 41.7% 5/12 slides 100% 12/12 slides · 30 hits 8.3% 1/12 slides Solution 20 slides 100% 20/20 slides 100% 20/20 slides · 123 hits
— 0/20 slides
30% 6/20 slides · 7 hits 35% 7/20 slides 100% 20/20 slides · 38 hits 50% 10/20 slides Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
— 0/2 slides
100% 2/2 slides 100% 2/2 slides · 8 hits
— 0/2 slides
Product 5 slides 100% 5/5 slides 100% 5/5 slides · 31 hits
— 0/5 slides
40% 2/5 slides 60% 3/5 slides 100% 5/5 slides · 17 hits
— 0/5 slides
Team 2 slides 100% 2/2 slides 100% 2/2 slides · 9 hits
— 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides
— 0/2 slides

Slide inventory

45
every slide · same image gating as the playbook
01
Slide 1
Includes date and company logos.front_matter
Open slide detail
02
other
Open slide detail
03
frame_situation
Open slide detailLoop · Golden Circle
04
summarize
Open slide detailLoop · Golden Circle
05
The slide uses a process-like flow with plus signs to indicate additive value components.summarize
Open slide detailLoop · Golden Circle
06
Includes headshots for leadership team and lists for board, advisors, and investors.introduce_nominees
Open slide detailBeat · Team
07
The slide uses a combination of bulleted achievements and a logo grid of FDA-approved drugs to establish credibility.establish_context
Open slide detailBeat · Team
08
Includes two tables: one for lead candidates and one for discovery programs.summarize
Open slide detail
09
The slide uses a split-screen layout to contrast clinical challenges with the specific reasons for treatment switching.diagnose_problem
Open slide detailBeat · Problem
10
Includes a line chart showing treatment duration and a pie chart showing patient outcomes.size_opportunity
Open slide detailBeat · Problem
11
Includes scatter plot for MMR correlation and bar chart for therapeutic index comparison.analyze_data
Open slide detailBeat · Problem
12
The slide outlines three strategic pillars (Drive Deeper Responses, Improve Tolerability, Enhance Safety & Convenience) and maps them to specific clinical develpresent_solution
Open slide detailBeat · Problem
13
Uses a before-after-bridge structure to contrast market limitations with product advantages.frame_problem
Open slide detailBeat · Problem
14
The chart uses a broken axis to represent the significantly larger patient population for HER2 overexpressing cancers compared to mutations.size_opportunity
Open slide detailBeat · Problem
15
The chart uses a logarithmic scale for selectivity. The right side provides a qualitative critique of competitor molecules.compare_peers
Open slide detailBeat · Problem
16
Includes a list of abbreviations at the bottom.summarize
Open slide detailBeat · Problem
17
plan_implementation
Open slide detailBeat · Problem
18
Includes a stylized chemical structure graphic.front_matter
Open slide detailBeat · Problem
19
Includes a timeline of key drug approvals and a survival probability chart.establish_context
Open slide detailBeat · Problem
20
The slide uses a split-screen layout to contrast clinical challenges with the rationale for treatment switching.diagnose_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
21
The slide uses a comparative table to frame the problem of current drug limitations, setting up a solution-oriented conclusion.compare_peers
Open slide detailBeat · SolutionLoop · Cost Of Inaction
22
Includes clinical trial data and resistance mutation analysis.summarize
Open slide detailBeat · SolutionLoop · Cost Of Inaction
23
The slide uses a split-screen layout to contrast current market realities with the company's vision, supported by a survival curve and a patient outcome pie chasummarize
Open slide detailBeat · SolutionLoop · Cost Of Inaction
24
The slide uses a custom table structure to show competitive positioning of ELVN-001 against existing TKI generations.diagnose_problem
Open slide detailBeat · SolutionLoop · Cost Of Inaction
25
The slide outlines the strategic positioning of a drug candidate (ELVN-001) by contrasting its desired profile against current standards of care.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
26
Includes structural biology diagrams of BCR-ABL protein domains and a table comparing binding conformations.present_framework
Open slide detailBeat · SolutionLoop · Cost Of Inaction
27
The table highlights key differentiators such as lower BCRP substrate status and improved plasma protein binding for ELVN-001.compare_peers
Open slide detailBeat · SolutionLoop · Cost Of Inaction
28
Includes both a competitive cellular phosphorylation table and a specific kinase selectivity table for ELVN-001.compare_peers
Open slide detailBeat · SolutionLoop · Cost Of Inaction
29
The slide uses a scatter plot for efficacy correlation and a bar chart for safety margin comparison.compare_peers
Open slide detailBeat · SolutionLoop · Cost Of Inaction
30
The slide uses a process-oriented layout to show the progression of clinical trials.plan_implementation
Open slide detail
31
Features a stylized chemical structure graphic.frame_situation
Open slide detail
32
Uses a before-after framing to contrast market limitations with product solution.frame_problem
Open slide detail
33
The chart uses a broken axis to represent the significantly larger patient population for HER2 overexpressing cancers compared to the initial focus areas.size_opportunity
Open slide detail
34
The slide contrasts established therapies with investigational ones, emphasizing the lack of selective TKIs and the resulting toxicity issues.compare_peers
Open slide detail
35
The slide highlights a gap in the market for a selective, irreversible TKI for brain metastases.compare_peers
Open slide detail
36
Includes a list of abbreviations at the bottom.summarize
Open slide detail
37
The table uses a heatmap-style color coding (green for favorable, red for unfavorable) to visualize potency differences.compare_peers
Open slide detail
38
The table highlights ELVN-002's superior selectivity (sparing EGFR) and better pharmacokinetic properties compared to competitors.compare_peers
Open slide detail
39
The slide uses a logarithmic scale for selectivity. The right side provides a qualitative critique of competitor molecules.compare_peers
Open slide detail
40
Data shows ELVN-002 efficacy and safety profile compared to Tucatinib and Poziotinib.analyze_data
Open slide detail
41
The slide compares efficacy (BLI signal) and PK (concentration over time) to demonstrate superior potency of ELVN-002 at lower exposures.analyze_data
Open slide detail
42
Includes references to Li et al. Cancer Disc 2020 and Abraham et al. J Clin Oncol 2019.analyze_data
Open slide detail
43
Includes a line chart showing concentration over time and a table summarizing safety margin folds at different doses.analyze_data
Open slide detail
44
Uses a process-oriented layout to show progression of clinical trials.plan_implementation
Open slide detail
45
The slide uses a stylized chemical structure as a background element.closing_ask
Open slide detail